Articles On Respiri (ASX:RSH)

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Research reports on ASX-listed companies, to download in full. **** -Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=04E6FD35-F066-D52A-FF94AEB002399CD2 -Carly Holdings ((C...

Whilst the prevalence of Artificial intelligence has boosted the US-tech sector, with the likes of Nvidia and C3.ai seeing their share prices increase by 219% and 265% respectively since the start of the year, Down Under, tech stock valuati...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

ShareCafeRespiri (ASX:RSH) – Webinar Presentation Marjan Mikel, CEO and Brian Leedman, Non-Executive Director – Respiri Limited (ASX:RSH) is leading the way in the development of innovative eHealth solutions that aim to improve the managem...

Research reports on ASX-listed companies, to download in full. **** –AFT Pharmaceuticals ((AFP)) – Edison Research: https://www.fnarena.com/index.php/download-article/?n=5CCC26AF-A670-63C8-370E356F819BE3C4 –Barrow Handley Global Share Fund...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

After a feeble start, the benchmark has rallied to close at +0.1% Newcrest and Newmont shake hands on Australia’s biggest goldie takeover Westar Resources shines bright with a 47% price hike   As far as days on the ASX go, that definitely...

Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The ASX got an Data Nerd Bailout when the ABS dropped happy-ish CPI data The benchmark recovers from early flesh wounds to end the day flat Ordinary Aussies ‘outraged’ over changes to super that will never, ever affect them The market has...

The ASX climbed 0.4% today after investors threatened it with a stick Mt Monger (ASX:MTM) wins the day by securing funding for it’s Canadian REE play New consumer survey suggests 42% of shoppers might be dumber than previously feared   Au...

Respiri (RSH) becomes the first Australian company to have its medical device receive reimbursement from Centres of Medicare and Medicaid Services in the US The medical device manufacturer can now have its patented wheezo device, used fo...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Respiri (RSH) begins enrolling patients with chronic obstructive pulmonary disease (COPD) in its wheezo remote patient monitoring (RPM) program in Arkansas Respiri will receive recurring revenues per patient per month in addition to devi...

After yesterday’s pre-Chrimbo spend-up, SPI Futures are down 66 points (-0.38%) this morning, threatening to wipe out yesterday’s 41-point gain. That’s on the back of some good/bad, depends-on-your-worldview news out of the US that data con...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Respiri’s wheezo RPM will be installed in New Mexico, USA Beamtree signs new distributor Bionomics welcomes new CEO   Respiri (ASX:RSH) has secured another primary care practice, Hand Family Healthcare, located in Clovis, New Mexico, USA....

Respiri (RSH) secures an additional primary care practice in New Mexico, US, for its wheezo remote patient monitoring (RPM) programThe company has completed the onboarding of the Hand Family Healthcare practice, which will run a wheezo RPM...

Respiri (RSH) begins onboarding patients in the short wheezo remote patient monitoring (RPM) pilot programRespiri, and partner Access Telehealth, will provide a full solution including the Remotli platform, patient engagement and remote mon...

Respiri (RSH) has secured its first primary care specialty practice in Georgia, USAs such, the company has welcomed its first patients with respiratory disorders to begin the ‘wheezo’ remote patient monitoring programThrough the program, Re...

ASX 200 down -0.4% Small cap index loses -1.7%  Way2VAT: killing it in the VAT space The small caps index has been smashed on Monday as the local Energy and Resources Sectors took fright from what is easily the scariest social unrest acro...

The US FDA conditionally approved Anteris’ DurAVR system Respiri partners with a leading US cardiac centre in Arkansas Emyria accepted into the National Institutes of Health (NIH) program Anteris gets FDA approval Heart specialist Anteri...

The ASX is set to end its four-day winning streak and slip on Monday Wall Street finished mixed after a shortened session China protests have spread across the country The ASX is poised to slip on Monday, ending its four-day winning strea...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Respiri’s (RSH) wheezo device and remote patient monitoring (RPM) solution have been selected by Minnesota Lung Centre (MLC) for a pilot programMLC treats patients with respiratory health needs and has launched this pilot program so it can...

ASX 200 halves gains on the run home  Small cap index closes about 0.7% higher Tinkler takes more Jameson, shares jumps 50%   Up strongly this morning following some epic 90’s style US leads on Friday… …the benchmark ASX200 is giving it...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Respiri (RSH) establishes a Philippine-based Company Centre of Digital Innovation Excellence following an internal review of its global growth requirementsThe Centre of Excellence will undertake the design and development of software underp...

ASX 200 down 1.6% Small caps short 1.3% Real Estate stocks hit ahead of FOMC meet   The benchmark killed Tuesday only to find its very own number was up today. The ASX 200 has spent the session retracing yesterday’s 1.3% gains – driven b...

The ASX 200 is vacillating Small caps are down over 1.3% Demetallica is a great name and it’s up 40% on takeover talk   The benchmark ASX 200 is flat as on Monday. The ASX Emerging Companies (XEC) index has lost 1.3%. REITs and Gold are h...

Opyl has a new experienced chairman to lead the company into its next stage of growth on the back of successful FY22 results and its flagship platform ready for international launch. Medtech Opyl (ASX:OPL) has announced the appointment of...

The ASX200 is down 0.24% dragged down by the tech sector Eight out of eleven sectors were lower, with Tech leading the losers CBA says the unemployment rate is at its lowest in 48 years   Despite creeping up earlier in the week the ASX 20...

Respiri gives update on US market Screening results from 19 of Emyria’s MDMA compounds have been returned Telix reports strong half-year results Respiratory disease specialist, Respiri (ASX:RSH), surged 14% this morning after updating the...

HeraMed signs US deal worth $500k Pregnancy medtech specialist, HeraMed (ASX:HMD), was up over 20% this morning after revealing a supply deal with US-based e-Lōvu Health. The expected revenue to HeraMED from the deal is approximately US$550...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

King’s College, London (KCL) receives a National Institute for Health Research (NIHR) funded UK paediatric asthma clinical trial using Respiri’s (RSH) wheezo device The £2 million trial will assess the impact of the device when combined w...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Literally every sector had a red month, but mining was the worst PayGroup gets surprise $120m takeover offer from US unicorn Deel Tempest Minerals signed JV to explore near the Karara Magnetite Iron mine June was a month of global econom...

Tech leads losses on local markets ASX 200 gives away early gains, XEC dives more than 1% again BNPL names big and small get smaller   Small Caps are sharply lower and the ASX 200 is wandering aimlessly on Wednesday as tech names tumble...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Health technology company Respiri (ASX: RSH) has unveiled a $1.5 million capital raising as it fast-tracks its expansion through the US respiratory health market, which is forecast to be worth US$85 billion by 2026. The funds will be used t...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

eHealth company Respiri (RSH) enters a trading halt ahead of a capital raise So far, there is no information on how much the company is aiming to raise or where the funds will be spent Under the halt, company shares will be paused until Fr...

Halo Technologies (HAL) shares have plunged 27.5 per cent since its ASX debut yesterday. The listing came after the company raised more than $36 million through an IPO priced at $1.20 per share. The Australian business offers global s...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...